Stay updated with breaking news from Chris Robillard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Paltusotine’s Phase 3 PATHFNDR-1 study enrollment complete and topline data expected in 3Q 2023Paltusotine’s Phase 3 PATHFNDR-2 study enrollment ongoing with topline data now expected in... | February 28, 2023
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...
11.04.2022 - SAN DIEGO, April 11, 2022 (GLOBE NEWSWIRE) - Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and ...
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer - read this article along with other careers information, tips and advice on BioSpace
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare